10-Q: Chain Bridge I Terminates Phytanix Merger, Faces Liquidation

Chain Bridge I, a SPAC, reported a Q2 2025 net income but terminated its business combination agreement with Phytanix Bio, raising substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net income of $5,793 for the three months ended June 30, 2025, a significant improvement from a net loss of $447,636 in the same period of 2024.
• The net loss for the six months ended June 30, 2025, was $357,847, a reduction from a $1.7 million loss in the prior year's comparable period.
• The cash balance as of June 30, 2025, was $2,856, a substantial decrease from $129,598 at December 31, 2024.
• The working capital deficit increased to $1,257,022 as of June 30, 2025.
• The previously announced Business Combination Agreement with Phytanix Bio, entered into on July 22, 2024, was mutually terminated on April 7, 2025.
• The company faces a mandatory liquidation date of November 15, 2025, if a business combination is not consummated.
• Management has identified substantial doubt about the company's ability to continue as a going concern.
• The company was delisted from Nasdaq on November 19, 2024, and its Class A ordinary shares now trade on the OTCQB Market under the symbol CBRRF.
• Sponsor contributions totaling $32,000 have been made to the Trust Account in 2025 to extend the company's life through August 15, 2025.
• A material weakness in internal control over financial reporting related to the adequate review and reconciliation of liabilities and prepaid expenses was identified.

Sentiment

Score: 2

Explanation: The termination of the primary business combination target, coupled with severe liquidity issues, a formal going concern warning, Nasdaq delisting, and a looming liquidation deadline, indicates a highly precarious financial and operational situation. While there was a small net income for the quarter, it is overshadowed by fundamental existential threats.

Positives

• Achieved a net income of $5,793 for the three months ended June 30, 2025, a significant improvement from a net loss of $447,636 in the prior year's comparable quarter.
• Reduced the net loss for the six months ended June 30, 2025, to $357,847, down from $1.7 million in the same period of 2024.
• General and administrative expenses decreased significantly for both the three-month ($275,283 vs $563,365) and six-month ($467,133 vs $1,073,421) periods compared to the prior year.
• Realized a gain from the change in fair value of derivative liabilities of $242,550 for the three months ended June 30, 2025, and a gain of $55,120 for the six months ended June 30, 2025, a substantial improvement from a $990,040 loss in the prior year's six-month period.
• The Business Combination Marketing Fee of approximately $8.1 million was waived by Cowen and Company, LLC as of December 29, 2023.

Negatives

• The Business Combination Agreement with Phytanix Bio was mutually terminated on April 7, 2025, leaving the company without a definitive merger target.
• The cash balance significantly decreased to $2,856 as of June 30, 2025, from $129,598 at December 31, 2024.
• The working capital deficit increased to $1,257,022 as of June 30, 2025.
• The company was delisted from Nasdaq on November 19, 2024, and now trades on the less liquid OTCQB Market, which may negatively impact investor interest and future capital raising efforts.
• A mandatory liquidation date of November 15, 2025, is approaching if a business combination is not completed.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• A material weakness in internal control over financial reporting related to the adequate review and reconciliation of liabilities and prepaid expenses was identified.
• Income from investments held in the Trust Account decreased for both the three-month ($55,876 vs $145,729) and six-month ($111,291 vs $489,249) periods compared to the prior year.
• The accumulated deficit increased to $(2,806,885) as of June 30, 2025, from $(2,367,244) at December 31, 2024.

Risks

• Inability to consummate a Business Combination by November 15, 2025, which would lead to mandatory liquidation and the potential for public shareholders to lose their investment.
• Substantial doubt about the company's ability to continue as a going concern due to its current liquidity condition and the looming mandatory liquidation date.
• Risk of being deemed an unregistered investment company under the Investment Company Act, potentially forcing the company to abandon its efforts to complete a business combination and liquidate, causing investors to lose the benefits of owning stock in a successor operating business.
• The delisting from Nasdaq and subsequent trading on the OTCQB Market may materially adversely impact the company's ability to locate another target for an initial business combination, and would likely cause liquidation, rendering warrants worthless.
• A material weakness in internal control over financial reporting related to the adequate review and reconciliation of liabilities and prepaid expenses could lead to financial misstatements.
• Geopolitical events, military conflicts, terrorism, sanctions, and adverse developments in the global economy and capital markets (e.g., rising energy costs, inflation, interest rates) could negatively affect the company's financial position, operations, and search for a target company.
• The company's election not to opt out of the extended transition period for complying with new or revised financial accounting standards may make its financial statements difficult to compare with other public companies.

Future Outlook

The company has until November 15, 2025, to consummate an initial Business Combination, after which it must cease operations, redeem Public Shares, and liquidate. The pro rata redemption price for public shares is expected to be at least $10.20 per share plus interest. While the company intends to apply to list its securities on Nasdaq Capital Markets upon consummation of a business combination, the failure to secure a new target following the termination of the Phytanix Bio merger and its current delisted status on Nasdaq will have a material adverse impact and likely lead to liquidation.

Management Comments

• Management continues to evaluate the current or anticipated military conflicts, including between Russia and Ukraine, and Israel and Hamas, terrorism, sanctions or other geopolitical events as well as adverse developments in the economy and capital markets, including rising energy costs, inflation and interest rates, in the United States and globally, on the industry and has concluded that while it is reasonably possible that these events could have a negative effect on the Companys financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statements.
• In connection with our assessment of going concern considerations... the Company has determined that the liquidity condition and the date for mandatory liquidation and subsequent dissolution raises substantial doubt about the Companys ability to continue as a going concern.
• Management has undertaken remediation steps to address the material weakness, including increasing management review processes over liabilities. This remediation is an ongoing process and there can be no assurance that it will effectively address the material weaknesses.

Industry Context

The SPAC industry faces increased regulatory scrutiny, particularly regarding the Investment Company Act, with proposed SEC rules (18/24 month safe harbor) highlighting the pressure on SPACs to complete business combinations quickly. Chain Bridge I's delisting from Nasdaq, its ongoing search for a target, and the formal going concern warning reflect the significant challenges faced by many SPACs that fail to identify and close a suitable merger within their mandated timelines. The termination of the Phytanix Bio merger further exacerbates these industry-specific pressures, placing the company in a highly precarious position within a competitive and regulated market.

Comparison to Industry Standards

• The company's failure to complete a business combination within 36 months of its IPO led to its delisting from Nasdaq on November 19, 2024, directly violating Nasdaq Listing Rule IM-5101-2, a key standard for SPACs.
• The company's current status of trading on the OTCQB Market is a significant downgrade from Nasdaq, indicating a failure to meet major exchange listing standards and a reduced market presence compared to its peers.
• The company's situation highlights the broader trend of SPACs struggling to find suitable targets and facing liquidation, contrasting sharply with successful SPACs that complete mergers and transition into operating companies, such as those that have successfully de-SPACed and maintained Nasdaq or NYSE listings.
• The company's contradictory statements regarding compliance with the SEC's proposed 18/24 month safe harbor for the Investment Company Act, while being nearly 48 months post-IPO without a completed business combination, indicates a significant deviation from the intended operational timelines for SPACs and raises concerns about regulatory compliance compared to industry best practices.

Management Changes

Corporate Governance

Related Party Transactions

• Fulton AC I LLC (Fulton AC) acquired 3,035,000 Class B ordinary shares and warrants to purchase 7,385,000 Class A ordinary shares from CBG and CB Co-Investment on December 29, 2023.
• CB Co-Investment's $1.15 million loan was converted into contingently issuable Private Placement Warrants (805,000 to Fulton AC, 273,431 to CBG, 71,569 to CB Co-Investment) upon consummation of a Business Combination.
• Fulton AC agreed to loan the Company up to $1.5 million via the Fulton AC Note (later exchanged for the Exchange Note), which is unsecured, non-interest bearing, and convertible into warrants. The outstanding balance was $491,248 as of June 30, 2025.
• Fulton AC entered into a Services Agreement with the Company on December 29, 2023, to provide office space, administrative, and support services for up to $30,000 per month. The outstanding balance was $180,000 as of June 30, 2025.
• Fulton AC agreed to indemnify the Trust Account for certain claims by third parties.
• CBG and CB Co-Investment agreed to vote their shares in favor of the Amendment Proposal and convert their Class B ordinary shares to Class A ordinary shares.
• The sponsor (Fulton AC) contributed $22,500 on February 16, 2024, and $5,000 per month starting May 16, 2024, to the Trust Account.
• The sponsor (Fulton AC) contributed $4,557 on November 16, 2024, and $4,557 per month starting December 16, 2024, to the Trust Account.
• The sponsor made contributions to the Trust Account in 2025 (Jan 16, Feb 14, Mar 17, May 15, June 16, Aug 11) totaling $32,000 to extend the company's life.
• Fulton AC agreed to reimburse the Trust Account up to $100,000 for dissolution expenses if the company is dissolved.
• Andrew Kucharchuk, the new CFO, is compensated pursuant to a consulting agreement with Fulton AC.

Stakeholder Impact

• Shareholders face significant uncertainty due to the terminated merger, delisting from Nasdaq, a formal going concern warning, and a looming liquidation deadline. Remaining shareholders risk substantial or total loss of their investment if no business combination is completed by November 15, 2025.
• Warrant holders face a high risk of their warrants expiring worthless if the company liquidates without completing a business combination.
• Management and directors' compensation and future roles are highly dependent on the company's ability to successfully identify and close a new business combination.
• Creditors, including holders of the Exchange Note and Bridge Financing Note, face uncertainty regarding repayment, particularly if the company is forced to liquidate, although obligations under Cayman Islands law to provide for claims of creditors would apply.
• Fulton AC, as a significant related party and lender, has a vested interest in the company's survival and successful business combination, having provided substantial financial support and services.

Next Steps

• Identify and consummate a new Business Combination by November 15, 2025, to avoid mandatory liquidation.
• Continue efforts to address the material weakness in internal control over financial reporting.
• If no Business Combination is completed, cease operations, redeem Public Shares, and liquidate the company.
• Apply to list securities on Nasdaq Capital Markets upon the successful consummation of a Business Combination.

Key Dates

Recommendation

The termination of the Business Combination Agreement with Phytanix Bio, coupled with the company's delisting from Nasdaq, severe liquidity issues, a formal going concern warning, and a mandatory liquidation deadline of November 15, 2025, creates an extremely high-risk investment profile. The company has repeatedly failed to complete a business combination within its extended timelines and faces significant challenges in securing a new target and relisting on a major exchange. While there was a small quarterly net income, it is overshadowed by fundamental existential threats. The risk of total capital loss for shareholders and warrant holders is substantial, making a 'strong sell' recommendation appropriate for any remaining holdings.

Keywords

SPAC, blank check company, Chain Bridge I, CBRRF, 10-Q, quarterly report, SEC filing, business combination, liquidation, going concern, Nasdaq delisting, OTCQB, Phytanix Bio, merger termination, financial results, risk factors, internal controls, warrants, trust account